Hangzhou KangQian Pharmaceutical Technology

Hangzhou KangQian Pharmaceutical Technology is a Chinese biotechnology company focused on the development and commercialization of innovative therapies for neurological and cerebrovascular diseases. The company is notably associated with the development and licensing of Edaravone/Dexborneol (Sanbexin), a neuroprotective agent used for the treatment of acute ischemic stroke. Hangzhou KangQian works in collaboration with major pharmaceutical entities like Simcere Pharmaceutical to advance clinical research and expand the therapeutic applications of its core assets. Its portfolio includes sublingual formulations designed to improve patient outcomes in stroke recovery and cognitive impairment.